Medpace Holdings, INC

Medpace Holdings, Inc. announced robust second quarter 2026 financial results, with significant year-over-year growth in revenue, net income, and EBITDA, alongside strong new business awards.

Medpace Holdings, Inc. announced the appointment of Brad W. Hansman as Executive Vice President, Operations, effective June 1, 2026.

Medpace Holdings, Inc. announced key governance changes approved at its 2026 Annual Meeting, including the removal of supermajority voting requirements and enhanced stockholder rights to call special meetings.

Medpace Holdings, Inc. announced robust first quarter 2026 financial results, including a 26.5% increase in revenue, alongside the planned retirement of its President.

Medpace Holdings, Inc. announced robust third-quarter 2025 financial results, with significant revenue and net new business growth, and provided an optimistic full-year 2025 financial guidance.

Medpace Holdings, Inc. announced robust second quarter 2025 financial results with significant revenue and EBITDA growth, alongside a strategic amendment to its credit facility reducing its line of credit to $10 million.

Medpace Holdings, Inc. announced robust financial performance for the second quarter of 2026, with significant year-over-year growth in revenue and net income.

Medpace Holdings reports strong Q1 2026 results with significant revenue growth and improved net income, driven by key therapeutic areas.

Medpace Holdings, Inc. announced robust financial results for the third quarter and nine months ended September 30, 2025, driven by significant revenue and net new business award increases.

Medpace Holdings, Inc. announced a significant increase in second-quarter revenue and net income, driven by growth in key therapeutic areas, while executing substantial share repurchases.

Medpace Holdings, Inc. announces increased revenue and net income for Q1 2025, along with an expansion of its stock repurchase program.

Medpace Holdings, Inc. announced a robust third quarter for 2024, with revenue increasing by 8.3% compared to the same period last year.

Medpace Holdings, Inc. announced robust financial results for fiscal year 2025, driven by significant revenue growth and continued strategic share repurchases.

Medpace Holdings, Inc. announces a robust fiscal year 2024 with significant revenue growth and an increase in its stock repurchase program, signaling continued financial strength and commitment to shareholder value.

Medpace Holdings, Inc. demonstrates robust growth in its 2023 annual report, marked by a significant increase in revenue and backlog.

August J. Troendle, President & CEO, a Director and 10% owner of Medpace Holdings, Inc., sold 7,238 shares of common stock on July 27, 2026.

Susan E Burwig, Exec. VP, Operations of Medpace Holdings, Inc., sold 7,500 shares of common stock on July 28, 2026 for $600.00 per share.

Robert O. Kraft, a Director at Medpace Holdings, Inc., has acquired 33 restricted stock units, converting them into common stock.

Stephen P. Ewald, General Counsel & Corp. Secy. of Medpace Holdings, Inc., reported transactions involving the acquisition and disposition of common stock.

Medpace Holdings, Inc. director Dani S. Zander was granted 1,110 stock options as part of standard board compensation.

Medpace Holdings, Inc. director Cornelius P. McCarthy III was granted 1,110 stock options as part of standard equity compensation.

Medpace Holdings, Inc. announces strong 2025 financial results, exceeding guidance, and proposes key corporate governance amendments for its 2026 Annual Meeting.

Medpace Holdings, Inc. has filed a definitive proxy statement with the SEC.

Medpace Holdings will hold its 2025 Annual Meeting of Stockholders virtually on May 16, 2025, to vote on director elections, auditor ratification, executive compensation, an incentive award plan, and a stockholder proposal.

Medpace Holdings, Inc. has filed a definitive proxy statement with the SEC.

Medpace Holdings is seeking stockholder approval to amend its certificate of incorporation to phase out the classified board structure, aiming for full declassification by the 2027 annual meeting.

Medpace Holdings, Inc. founder August J. Troendle significantly reduced his stake, selling common stock worth over $149 million in open market transactions.

August J. Troendle, a key reporting person for Medpace Holdings, Inc., has increased his beneficial ownership to 19.5% of common stock through recent option grants and exercises.

The Vanguard Group has filed an amended Schedule 13G, reporting a 0% beneficial ownership in Medpace Holdings Inc. following an internal realignment.